SAPA MINE Salon RecapJPM Meetups & Strategic Recaps

📍 Princeton, NJ | February 27, 2026

On February 27, 2026, SAPA MINE (Meet with Investors and Network with Entrepreneurs) hosted its second exclusive in-person salon, “JPM Meetups & Strategic Recaps,” in Princeton, New Jersey. The event brought together biotech entrepreneurs, investors, business development leaders, and strategic decision-makers for an in-depth reflection on post-JPM insights and forward-looking trends for 2026.

Special thanks to Hill Wallack LLP for generously hosting the venue, and to Advanced CTS Corp. (ACTS) for sponsoring the event.

Registration, Networking & Dinner

Guests arrived at 6:00 PM and engaged in informal networking over dinner and drinks. Early discussions centered on JPM takeaways, cross-border collaboration, capital deployment, and business development opportunities. Small discussion circles naturally formed, reflecting strong engagement and shared interests among attendees.

Opening Remarks & Sponsor Introduction

The SAPA Immediate-Past President, Jack Wu, delivered the welcome remarks and provided an overview of SAPA, highlighting its mission and dedication to the community.

Irene Wu from the SAPA membership team, introduced the benefits of SAPA membership and opportunities for volunteer involvement.

The SAPA MINE leadership, led by Stephen Xue, welcomed participants and shared the vision behind the salon series: creating a high-trust, high-signal environment for strategic exchange beyond large conferences.

ACTS introduced its role as an FDA-registered drug distribution wholesaler, highlighting operational insights in New Jersey and considerations for emerging biotech companies.

Quinn K. Zhao (Hill Wallack LLP) introduced the firm and its commitment to support innovation.

Startup Pitch: ACON Pharmaceuticals

Dr. Xudong Yuan, CEO of ACON Pharmaceuticals, presented the company’s pipeline, clinical positioning, and upcoming financing milestones.

The panel and audience provided feedback on:

• Competitive differentiation

• Clinical milestone design

• Financing timing and capital efficiency

• Global licensing and partnership strategy

• Strategic positioning: platform vs. pipeline-focused company

This focused dialogue exemplified the salon’s emphasis on practical, high-value exchanges.

Opening Perspective: Biotech M&A & Deal Flow

Brian Yang, Editorial Contributor at STAT, framed the discussion with a macro view of JPM and biotech deal dynamics. Notable trends included:

• Large-cap pharma pursuing GLP-1, oncology, and cell therapy assets.

• Strategic licensing and acquisitions in China, especially siRNA and oncology

• Growing cross-border collaboration and asset sourcing

Key observations:

• Multinational pharma expanding R&D and deal activity in China

• Mid-sized biotechs leveraging China’s clinical and scientific ecosystem

• Investors increasingly targeting early-stage, innovation-driven assets

• U.S. capital gradually re-engaging with China biotech and new company formation

• Chinese investors scaling infrastructure to support sustainable growth

Strategic Implication: M&A remains a core growth driver for biotech. In 2026, sustained deal activity is expected, supported by clearer strategy and structured cross-border capital collaboration.

Panel Discussion & Q&A

Panelists included:

• Wendy Pan, Partner & Chair, Asia Life Sciences, Goodwin

• Brian Yang, Editorial Contributor, STAT

• Ran He, Founder & Partner, THC Lawyers

• Fernando (Fern) Sallés, PhD, CLP, Pteropsida Ventures, LLC

• Jack Wu, PhD, MBA, Senior Director, Takeda

Key Themes:

JPM Reflections: Panelists highlighted a cautious but rational investment environment. While mega-rounds were less frequent, high-quality assets continued to attract investor attention. Valuation discipline and clear clinical value propositions were emphasized.

China Deal Trends & Cross-Border Dynamics:

• Phase 1 clinical development in China is critical for early validation

• Growing confidence in China-generated clinical data

• Cost and speed advantages in trial execution

• AI adoption in drug discovery, clinical operations, and productivity

• Shift from early-stage to more clinically advanced assets

Trust, data quality, and regulatory alignment were emphasized as key factors shaping future cross-border collaboration.

30-Second Elevator Introductions & Networking

Like the first SAPA MINE Salon, the most engaging part of the evening was the structured 30-second attendee introductions. Each participant shared their name, organization, and collaboration interests, creating immediate clarity and fostering highly efficient networking. Many attendees exceeded the goal of connecting with eight or more new peers, making this segment a highlight of the event.

Closing Reflections

The February SAPA MINE Salon highlighted the value of curated, high-trust gatherings in the evolving biotech landscape. By combining strategic insight, startup visibility, and peer-level exchange, the event fostered forward-looking dialogue and meaningful collaboration.

SAPA MINE remains committed to fostering cross-border collaboration, capital insight, and community-driven strategic exchange, and looks forward to welcoming attendees to future salons.